norelgestromin (LNGO)

transdermal hormonal contraceptive

Also Known As:

LNGO; 17-deacetylnorgestimate; 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, oxime, (17alpha)-; levonorgestrel oxime; levonorgestrel oxime, (3E,17alpha)-isomer; levonorgestrel oxime, (3Z,17alpha)-isomer; progestin norelgestromin

Networked: 22 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Friedman, Andrew J: 3 articles (06/2005 - 02/2003)
2.	Pasqualini, Jorge R: 2 articles (12/2009 - 02/2003)
3.	Jick, Hershel: 2 articles (07/2007 - 03/2006)
4.	Kaye, James A: 2 articles (07/2007 - 03/2006)
5.	Fisher, Alan C: 2 articles (06/2005 - 06/2005)
6.	Lelle, I: 2 articles (07/2004 - 01/2004)
7.	Prifti, S: 2 articles (07/2004 - 01/2004)
8.	Rabe, T: 2 articles (07/2004 - 01/2004)
9.	Strowitzki, T: 2 articles (07/2004 - 01/2004)
10.	Alfonso, Alfaro-Rodríguez: 1 article (06/2022)

Related Diseases

1.	COVID-19 06/17/2022 - "Norelgestromin and ethinylestradiol TP could be a safe and effective treatment for moderate and severe COVID-19 patients." 06/17/2022 - "The objective of the current study was to evaluate the additional treatment with norelgestromin and ethinylestradiol in TP on the clinical and biochemical evolution of COVID-19 patients. " 06/17/2022 - "The present is a clinical-trial pilot study that included subjects diagnosed with COVID-19, randomized into two groups; the experimental Evra® TP (norelgestromin 6 mg and ethinylestradiol 0.60 mg) was administered such that it was applied on arrival and replaced at day 8 and day 15. " 06/17/2022 - "Effect of Norelgestromin and Ethinylestradiol in Transdermal Patches on the Clinical Outcomes and Biochemical Parameters of COVID-19 Patients: A Clinical Trial Pilot Study."
2.	Acne Vulgaris 07/01/2004 - "The synthetic progestins, norgestimate and norelgestromin, were designed to minimize the adverse effects such as acne, hirsuitism and metabolic changes observed with older oral contraceptives while maintaining contraceptive effectiveness and cycle control. " 01/01/2006 - "Norgestimate and norelgestromin mimic the physiologic effects of progesterone at the progesterone receptor; however, norelgestromin has negligible direct or indirect androgenic activity, suggesting that it may be suitable for women with disorders related to androgen excess (such as hirsutism, acne, and lipid disorders).Contraceptive effectiveness is usually a function of the efficacy of a contraceptive in combination with compliance with its dosing regimen. "
3.	Hirsutism 01/01/2006 - "Norgestimate and norelgestromin mimic the physiologic effects of progesterone at the progesterone receptor; however, norelgestromin has negligible direct or indirect androgenic activity, suggesting that it may be suitable for women with disorders related to androgen excess (such as hirsutism, acne, and lipid disorders).Contraceptive effectiveness is usually a function of the efficacy of a contraceptive in combination with compliance with its dosing regimen. "
4.	Venous Thromboembolism 01/01/2015 - "We provided information of this new TCDS compared with the only TCDS available on the market that contains EE and norelgestromin, and has a higher EE exposure than a COC with 35 µg of EE potentially increasing the risk of venous thromboembolism. " 05/01/2012 - "To date, 13 studies have provided data on the risk of venous thromboembolism associated with combined oral contraceptives containing drospirenone or the norelgestromin-containing contraceptive patch. " 03/01/2006 - "There is concern that a new transdermal contraceptive patch containing ethinyl estradiol (EE) and the progestin norelgestromin increases the risk for venous thromboembolism (VTE) compared to previously marketed oral contraceptives (OCs). " 07/01/2007 - "In 2006, we published a study that indicated that the new transdermal contraceptive patch containing ethinyl estradiol (EE) and the progestin norelgestromin did not increase the risk for venous thromboembolism (VTE) compared to oral contraceptive containing norgestimate and 35 microg of EE. " 01/01/2022 - "Compared with non-use, starting the use of gestodene and ethinylestradiol (adjusted odds ratio [aOR] 2.85; 95% CI 1.62-5.03), drospirenone and ethinylestradiol (aOR 1.55; 95% CI 0.98-2.44), desogestrel and ethinylestradiol (aOR 1.97; 95% CI 0.99-3.92), and transdermal patch releasing norelgestromin and ethinylestradiol (aOR 5.10; 95% CI 1.12-23.16), as well as continuing the use of gestodene and ethinylestradiol (aOR 2.60; 95% CI 1.61-4.21), drospirenone and ethinylestradiol (aOR 1.55; 95% CI 1.02-2.37), cyproterone-acetate and estrogen/ethinylestradiol (aOR 1.66; 95% CI 1.06-2.61), and vaginal ring releasing etonogestrel and ethinylestradiol (aOR 3.27; 95% CI 1.95-5.48) were associated with venous thromboembolism risk. "
5.	Breast Neoplasms (Breast Cancer) 02/01/2003 - "In the present study, we demonstrated in T-47D and MCF-7 human breast cancer cells that norelgestromin (NGMN) (a metabolite of norgestimate) is a potent inhibitory agent of the estrone sulfatase activity. " 07/01/2004 - "Induction of androgen receptor activity by norgestimate and norelgestromin in MDA-MB 231 breast cancer cells." 02/01/2003 - "Norelgestromin as selective estrogen enzyme modulator in human breast cancer cell lines. " 12/01/2009 - "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities. "

Related Drugs and Biologics

1.	Contraceptive Agents (Contraceptives)
2.	norgestimate
3.	Progesterone
4.	Progesterone Receptors (Progesterone Receptor)
5.	Lipids
6.	Androgens
7.	Ethinyl Estradiol (Estinyl)
8.	drospirenone
9.	Oral Contraceptives
10.	Combined Oral Contraceptives

Related Therapies and Procedures

1.	Contraceptive Effectiveness
2.	Transdermal Patch
3.	Female Contraceptive Devices (Vaginal Ring)
4.	Drug-Eluting Stents
5.	Hormone Replacement Therapy (Therapy, Hormone Replacement)